Fig. 5

Validation by in vitro experiments and molecular docking. (A) The proliferative ability of HT29 and LS180 cells that disposed in different concentrations of isorhamnetin, evodiamine, quercetin and rutaecarpine (0.5 µM, 1 µM, 2 µM, 4 µM, 8 µM and 16 µM). Schematic diagram (B) and stereogram (C) showed the binding pattern of rutaecarpine and TNF-α in molecular docking. (D) The supernatant concentration of TNF-α after HT29 and LS180 cells pretreating with rutaecarpine (0.5 µM, 1 µM, 2 µM and 4 µM). Data was showed as mean or mean ± SD.